Highest-materiality recent filing
DataMeds AI Q2 net loss widens to $18.4M; revenue up 14% sequentially
Revenue $1.779M, up 14% QoQ, beating management projections.
Datavault to distribute 50 Meme Coins per DataMEDS share to holders as of Aug 7
Record date Aug 7, 2026; payment begins Sept 9, 2026, subject to Datavault board's right to change or revoke.
MEDS to acquire QLPM IP from EOS and Scilex, expand Datavault AI Health license, and acquire controlling interest in Tollo Health (HLH).
DataMeds AI updates record date for Dream Bowl 2026 Meme Coin distribution to August 7, 2026
Record date for Dream Bowl 2026 Meme Coin distribution moved to August 7, 2026; holders receive 50 coins per share.
Wellgistics Health changes name to DataMeds AI, Inc.; ticker to MEDS on July 22
Name change to DataMeds AI, Inc. effective July 22, 2026; no stockholder vote required.
Wellgistics Health gets Nasdaq equity-compliance extension to Oct 12, regains bid-price rule
Nasdaq grants extension to Oct 12, 2026 to meet $2.5M min. stockholders' equity; current equity is $(12.4M).
Wellgistics Health 8-K amendment: no material new information for investors
Amendment No. 2 replaces Exhibit 4.3 (Placement Agent Warrant form) in the prior 8-K.
New $21M oversubscribed convertible debt refinances all outstanding convertible debt; no interest; converts at $6.00/share.
Notes aggregate principal $21.1M for $16.9M cash (20% OID); zero interest; mature in 12 months.
Expanded Datavault license and DelivMeds AI create IP for tokenized healthcare data management via EinsteinRx™.
Binding term sheet with Datavault AI (DVLT), Scilex (SCLX) and others to form DelivMeds AI; combined asset value expected $4B (subject to fairness opinion).
Wellgistics Q1 revenue $0.93M, net loss $7.7M; terminates Neuritek/WellCare LOIs; guides Q2 ~$1.78M
Revenue $0.93M in Q1 2026 vs $0.49M Q4 2025; expects Q2 rev $1.78M (with $0.86M recognized through May 18).
Wellgistics Health to report Q1 2026 results on May 19 after market close
Wellgistics Health will announce Q1 2026 financial results after market close on Tuesday, May 19, 2026.
Wellgistics withdraws preliminary proxy statement; continues evaluating strategic transactions
Filed request with SEC to withdraw Preliminary Proxy Statement on Schedule 14A filed May 14, 2026.
Wellgistics Health subsidiary enters forbearance agreement on $1.77M debt
Wellgistics, LLC acknowledges $1.77M owed to Marco Capital under Nov 2024 loan; MCI forbears through June 15, 2026.
Wellgistics Health enters Amended Settlement Agreement with Silverback Capital; no terms disclosed
Amended Settlement Agreement with Silverback Capital Corporation dated February 9, 2026.
Wellgistics receives Nasdaq deficiency notice; forms JV with KareRx hub
Received Nasdaq deficiency letter on Apr 13, 2026 for failing minimum $2.5M stockholders' equity; equity was -$12.4M.
Wellgistics Health forms joint venture with KareRx Hub, issuing up to $2M in stock for 51% stake
Wellgistics holds 51% membership interest in new LLC Healthstar; Kare Rx Hub holds 49%.
Company terminated Settlement Agreement with Silverback Capital Inc., effective April 3, 2026.
Wellgistics Health issues $1.25M in promissory notes at 20% discount to accredited investors
Company entered Note Purchase Agreement for up to $1,250,000 aggregate principal; purchase price $1,000,000 (20% OID).
Wellgistics Health secures preferred EBV pricing via Kare PharmTech revenue-share deal
Entered Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC on March 6, 2026 for product 'KARE Verify' (insurance eligibility & benefits verification).
Wellgistics launches medical food Forzet for GLP-1 muscle loss targeting $70B market
Forzet is a medical food for dietary management of muscle loss during weight loss therapies, aimed at GLP-1 drug users.
Wellgistics settles $10.7M liabilities via equity at $0.25–$2.25/share; appoints consulting CBO
Settled ~$10.7M liabilities with Silverback Capital via court-approved Section 3(a)(10) share issuance.
Wellgistics Health partners with NFL Alumni Health to deploy AI pharmacy tech for former NFL players
Partnership leverages EinsteinRx AI platform and PharmacyChain smart contracts for healthcare optimization.
Two directors resign from Wellgistics Health board effective Feb 1, 2026
Steven Lee (Ethics Committee) and Howard Doss (Audit Committee chair) resigned immediately.
Wellgistics Health issues up to $8.125M secured convertible notes at 20% OID
Issued $8.125M aggregate principal of secured convertible notes; purchase price $6.5M (20% OID).
Issued up to $3,125,000 aggregate principal convertible notes; purchase price $2.5M (20% original issue discount).
Wellgistics sets Dec 19 record date for Dream Bowl meme coin token distribution
Record date of December 19, 2025 for Dream Bowl 2026 Meme Coin tokens.
Stock closed below $1.00 for 30 consecutive business days (Oct 27–Dec 9, 2025); violates Nasdaq Listing Rule 5550(a)(2).
Wellgistics launches Brenzavvy targeting $16B SGLT-2 inhibitor market
Brenzavvy launch targets 33M type II diabetics in US with out-of-pocket costs above cash price.
Wellgistics Health declares stockholder distribution of Dream Bowl 2026 Meme Coin
Record date December 19, 2025; each share receives one Dream Bowl 2026 Meme Coin.
Wellgistics licenses DataVault AI smart contract IP for PharmacyChain; $2.5M upfront plus royalties
Upfront license fee of $2.5M due by Dec 31, 2025; ongoing 13% royalty on PharmacyChain net profit.
Wellgistics Health sponsors Dream Bowl 2026, plans meme coin airdrop to shareholders
Sponsorship fee of $250,000 for Dream Bowl XIV in Arlington, TX, Jan 8-11, 2026.
Wellgistics Health pays $2.5M for exclusive license of DataVault AI patents for PharmacyChain
License fee of $2.5M to DataVault AI, payable by Dec 31, 2025; plus 13% royalty on net profit from PharmacyChain.
Wellgistics Q3 net loss widens to $33.9M ($0.46/share) on stock-based comp
Q3 2025 net operating loss $33.878M vs $1.867M in Q3 2024; net loss per share $0.46 vs $0.04.
Auditor UHY resigns citing former CEO resignation info; Suri & Co. re-engaged
UHY LLP resigned as auditor on Nov 11, 2025 due to information from former CEO's resignation not yet investigated.
Wellgistics Health issues ~10.7M shares from warrant exercise and debt conversions
On Oct 24, warrant holders exercised 3,111,429 shares at $0.70, raising $2.18M.
SaaS agreement with DataVault AI (NASDAQ: DVLT) to develop PharmacyChain, a manufacturer-to-patient blockchain platform.
Wellgistics signs non-binding LOI with DataVault for blockchain pharmacy contract platform
Non-binding LOI to integrate DataVault's blockchain smart contracts (PharmaChain) into Wellgistics' prescription fulfillment network.
Wellgistics Health re-appoints Prashant Patel as interim CEO; multiple executive departures
Prashant Patel re-appointed President, Interim-CEO, and Board member after August 2025 resignation.
CEO, COO, CFO resign at Wellgistics Health; interim CFO appointed
CEO Brian Norton, COO Tony Madsen, and CFO Mark DiSiena resigned effective Oct. 6, 2025.
Wellgistics Health removes two directors, appoints four new directors and a President
Rebecca Shanahan and Michael Peterson removed as directors effective Oct 1, 2025 by majority stockholder consent.
Public offering of 7,142,862 common shares and warrants to purchase an equal number, at $0.70 per unit; gross proceeds ~$5M.
Wellgistics Health to present at three investor conferences in September 2025
CEO Brian Norton will present at H.C. Wainwright 27th Global Investment Conference on Sept 8, 2025.
Wellgistics Health enters $1.3M loan and launches HubRx AI engine for prescription hub services
Entered $1.3M Business Loan with Agile Capital Funding; matures April 8, 2026; weekly payments of $58,500.
Pro forma revenue for H1 2025 was $18.65M, up 2.2% from $18.25M in H1 2024.
Wellgistics Health terminates $50M ELOC, President resigns, launches XRP payment program
Terminated $50M equity purchase agreement with Hudson Global Ventures without penalty; no termination fees.
Wellgistics Health converts $8.1M debt to equity, amends acquisition payment terms
Remaining $8.14M closing cash payment converted into 7,606,785 shares of common stock; reduces short-term debt.
Wellgistics Health dismisses Suri & Co., appoints UHY LLP as new auditor
Board approved dismissal of Suri & Co. on July 7, 2025, and engagement of UHY LLP effective same date.
Wellgistics Health posts revised investor presentation; no specific changes disclosed
Company updated its investor presentation on its website on May 15, 2025.
On May 20, 2026, in connection with the Term Sheet described in Item 1.01 of this Current Report on Form 8-K, the Board of Directors of Wellgistics Health, Inc. (the “Company”) appointed Gerald Commissiong as Interim Co-Chief Executive Officer of the Company, effective immediately.
Mr. Balu’s decision to resign is not the result of any dispute or disagreement with the Company, the Company’s management or the Company’s Board of Directors on any matter relating to the Company’s operations, policies or practices.
On April 22, 2025, the Board of Directors of Wellgistics Health, Inc. (the “Company”) appointed Mark DiSiena as Chief Financial Officer of the Company, effective as of April 22, 2025
Sajid Sayed informed the Company’s board of directors of his intent to resign as a director of the Company, effective immediately.
the Board appointed Michael L. Peterson to fill the vacancy created as a result of Mr. Sayed’s departure.
Mr. Norton will succeed Timothy Canning, who served as the Company’s Chief Executive Officer since January 18, 2024, and who is resigning from his position, effective as of the Effective Date.
promoted Brian Norton to serve as the Company’s Chief Executive Officer effective as of February 28, 2025
Max materiality 0.85 · Median 0.65 · Most common event other_material